Monday-Friday 6:00am – 5:00pm | Saturday 6:00am – 12:00pm
Validation and 3 years of clinical experience in using an AI algorithm as a second read system for prostate cancer diagnosis
May 29, 2024Prostate cancer ranks as the most frequently diagnosed cancer in men in the USA, with significant mortality rates.
CorePlus Expands Use of AI Tools to Routine Cancer Diagnosis
May 29, 2024Back in June 2020, CorePlus Servicios Clínicos y Patológicos LLC (Carolina, Puerto Rico) became the first independent lab in the…
High risk HPV testing for cervical cancer screening in a Puerto Rican population
May 29, 2024The human papillomavirus (HPV) is the principal cause of cervical cancer and can cause up to six different types of…
Comparative analysis of onychomycosis in Puerto Rico using molecularand conventional approaches
May 29, 2024Onychomycosis is responsible for 50% of all nail infections. It is the most frequent nail ailment in adults and is…
CorePlus and Ibex show real world success with AI for routine cancer diagnosis
January 5, 2024CorePlus and Ibex show real world success with AI for routine cancer diagnosis.
ArteraAI Announces Research Agreement with CorePlus
January 5, 2024ArteraAI, a developer of AI-based cancer tests, has partnered with CorePlus, a CLIA-certified pathology laboratory in Puerto Rico.